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Abstract
Some antipsychotic drugs are metabolized in the liver, leading to active metabolites. These metabolites can 
maintain the effect of the original substrate or display different pharmacokinetic or pharmacodynamic properties, 
and that can be translated by a different profile of responses and interactions to clinical level. Among these is 
risperidone, whose active metabolite, 9-OH-risperidone, is known as paliperidone and has been marketed as such. 
In this review, we analyze the differential pharmacological aspects between risperidone and paliperidone, both from 
the pharmacokinetic (bioavailability, effect of CYP450 and P-glycoprotein, etc.) and pharmacodynamic perspectives 
(affinity for dopaminergic and/or serotonergic receptors, speed of dissociation from dopamine receptors, serotonin 
5-HT2Areceptor occupancy>D2, etc.) as well as differential electrophysiological profile and neuroprotective role. The 
pharmacological differences between the two drugs could explain the differential clinical response exhibited by 
schizophrenic patients treated with both agents, as well as some differences in tolerability profile and drug interactions. 
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Introduction
The synthesis of chlorpromazine in December, 1950, and the 
recognition of its antipsychotic properties that followed in 1952 [1,2], 
together with reserpine’s introduction for clinical use in 1953 [3,4], 
are two of the foundational events that together marked the so-called 
“psychopharmacological revolution.” Next, Paul Janssen’s discovery 
of haloperidol’s antipsychotic properties in the late 1950s and its 
subsequent commercialization [5,6] opened the door to a new world 
of hope in the treatment of psychosis, offering a selective, effective 
treatment for schizophrenic patients [7,8]. These options were a 
marked improvement from ‘biological therapies’, which were remedies 
that merely provided palliative and largely transient relief with dubious 
effectiveness [9]. 
In 1959, a Swiss company by the name of Wander selected a 
preparation with very specific pharmacological behavior from a series 
of tricyclic compounds. It did not cause catalepsy, did not influence 
apomorphine-induced stereotypes, and at high doses, it inhibited the 
escape reflex and arousal reactions through midbrain stimulation. This 
drug later came to be known as clozapine [10]. In light of that profile, 
despite several researchers’ rejection of it, Jules Angst succeeded in 
clinically demonstrating that it was an effective antipsychotic with no 
extrapyramidal symptoms [11]. Paul Janssen argued that since it did 
not induce catalepsy, it could be considered a neuroleptic, but clinical 
results obliged him to admit that if clozapine was a neuroleptic at all, it 
was an “atypical antipsychotic” [12]. 
In an effort to improve upon haloperidol’s pharmacological 
properties, Janssen discovered that pipamperone, an agent introduced 
in the year 1961, whose pharmacological and clinical profile was distinct 
from haloperidol and all other known antipsychotic drugs at the time, 
had considerable anti-tryptamine ability [13] and brought about 
resocializing effects [14]. While no connection was drawn at the time 
between that clinical feature and its antiserotonergic properties, some 
authors argue that pipamperone was the first atypical antipsychotic, 
albeit a premature one. In fact, when risperidone was created, Janssen 
suggested it was a more potent version of pipamperone. Synthesized in 
the year 1984, risperidone’s pharmacological properties were similar 
to pipamperone’s in that both block more serotonin than dopamine 
receptors; yet risperidone was three-hundred times more potent than 
pipamperone. Meanwhile, both drugs were stronger antagonists at 
those receptors than clozapine [5], which had been considered the gold 
standard of atypical antipsychotics. These findings laid the groundwork 
for the hypothesis that blocking serotonin 5-HT2 receptors and 
to a lesser extent dopamine D2 receptors, is the source of atypical 
antipsychotic effects [15]. From a clinical standpoint, building on that 
hypothesis has yielded the best results. From it most new antipsychotic 
agents were developed, termed in the field as “second-generation”, 
or more commonly “atypical”, antipsychotics [7,16,17], these have 
included clozapine, risperidone, olanzapine, ziprasidone, sertindol, 
quetiapine, and asenapine, among others [18]. 
Yet the label “atypical” encompasses a group of antipsychotics that, 
despite belonging to the same therapeutic class and sharing certain 
pharmacodynamic features, are vastly different, clinically speaking. 
Pharmacological differences may influence how a drug’s effects manifest 
themselves and how long they last, whether therapeutic or adverse. Most 
antipsychotics are metabolized by the liver, usually producing inactive 
metabolites. In some cases, however, antipsychotics’ biotransformation 
can produce active metabolites capable of sustaining the original 
substrate’s effects, or of taking on different pharmacokinetic or 
pharmacodynamic properties. This has been observed experimentally 
“in vitro” as well as “in vivo”. This can translate to a different profile of 
responses and interactions, clinically speaking. Of the antipsychotics in 
which the active metabolites have been reported (Table 1), risperidone 
stands out; its active metabolite, 9-OH-risperidone, has been labeled 
and sold as paliperidone. The following review will refer to differential 
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characteristics of two antipsychotics: the original risperidone and its 
active metabolite, paliperidone. 
9-OH-Risperidone, the Active Metabolite in Risperidone
Risperidone is metabolized primarily by cytochrome P450-2D6 
(CYP2D6), giving way through hydroxylation to the active metabolite 
9-OH-risperidone (Figure 1). Administering paliperidone, meanwhile, 
there is no conversion into risperidone. Early studies suggested that the 
actions of risperidone and its primary metabolite, 9-OH-risperidone, 
were pharmacologically similar, and that by administering risperidone, 
pharmacological activity could be attributed to the total plasma 
concentrations of risperidone and 9-OH-risperidone together. 
Similarly, risperidone and 9-OH-risperidone are considered to 
have similar pharmacological activity, so presumably, the two together 
explain risperidone’s antipsychotic component [20]. In fact, it was 
postulated that modifying the activity of CYP2D6 could alter the 
relationship between substrate and metabolite without altering overall 
pharmacological response, given that a decrease in 9-OH-risperidone 
cancels out any corresponding increase in risperidone. Applying that 
criterion, the presence of genetic polymorphism from CYP2D6, or 
of an enzyme inhibitor or inductor, is irrelevant to the final clinical 
outcome [21,22]. 
To date, several articles have demonstrated that risperidone and 
9-OH-risperidone have neither the same therapeutic, pharmacological 
potency, nor the same toxicological activity [23]. When risperidone is 
administered, the results are a direct effect of that molecule as well as 
effects deriving from its active metabolite, 9-OH-risperidone. Bear in 
mind that most patients who take risperidone orally exhibit plasma 
levels of 9-OH-risperidone between 5 and 10 times higher than their 
plasma levels of risperidone [23]. 
We believe that simple fact is key to clinical practice; risperidone’s 
pharmacokinetic and pharmacodynamic differences from paliperidone, 
which will be elaborated on in this paper, are considerable and warrant 
discussion. Yet as some authors argue [24], in other ways, the two 
agents behave similarly, both qualitatively and quantitatively. 
From 9-OH-risperidone (risperidone’s metabolite) to 
paliperidone: A different pharmacological entity 
Strictly speaking, paliperidone (9-OH-risperidone) is the primary 
active metabolite in risperidone, having been hydroxylated at position 
9 during the first phase of metabolism in the liver. This step is catalyzed 
mainly by isoenzyme CYP2D6, and to a lesser extent by CYP3A4 [25] 
(Figure 1). 
Nowadays, paliperidone is considered an atypical antipsychotic 
belonging to the chemical family of benzisoxazole derivatives, whose 
molecular formula is C23H27FN4O3 and whose molecular weight is 
426.49. Paliperidone is a racemic mixture of two enantiomers of similar 
potency. 
Paliperidone was approved in the form of extended-release 
(Paliperidone ER) tablets by the Food and Drug Administration 
(FDA) on December 19, 2006 as a new therapeutic agent to treat 
schizophrenia under the commercial name Invega®. According to the 
FDA’s statement, it is a new molecular entity containing an active 
substance never before approved for commercial use in any form in 
the United States (Drugs@FDA, 2006). The European Commission, 
meanwhile, authorized the medication Invega® as valid for commercial 
use in the entire European Union, favoring Janssen-Cilag International 
NV, on June 25, 2007 (Invega® European Public Assessment Report. 
Scientific discussion, 2007). Next, the World Health Organization 
(WHO) deemed paliperidone (ATC N05AX13) distinct from other 
antipsychotics, specifically risperidone (ATC N05AX08) (The WHO 
Collaborating Centre for Drug Statistics Methodology ATC/DDD, 
2007).
Paliperidone ER is the first oral antipsychotic to utilize the osmotic 
system, known as OROS® (Oral Osmotic System) (Alza Corporation, 
Mountain View, California) or Push-PullTM that can control the how 
fast paliperidone is released [26,27]. The osmotic formulation of 
paliperidone ER results for plasma profile with fewer oscillations than 
risperidone (Figure 2).
Paliperidone Er’s Differential Pharmacokinetic Profile 
As Compared To Oral Risperidone
Table 1 details the main pharmacokinetic features of paliperidone 
ER, comparing them to risperidone and other atypical antipsychotics, 
and to haloperidol as a point of reference for classical neuroleptics. 
Absorption
Generally speaking, antipsychotic medications are highly 
liposoluble, which explains their good, though not total, absorption 
through the digestive tract following oral ingestion, and volume of 














Haloperidol 2-30 (100) 3-6 15-30 15-20 40-80 90-94
Clozapine 150-450 (900) 1-6 12-36 4-8 40-60 97
Risperidone 4-16 (16) 2 2,8 1-1,5 66-82 89
Olanzapine 10-30 (20) 5-8 33 10-20 60-80 93
Quetiapine 150-750 (800) 1-1,5 5,8-6,6 10 100 83
Ziprasidone 80-160 3,8-5,2 3,2-10 1,5 60 > 99
Amisulpride 400-1200 (1200) 1,5-4 12 5,8 48 16
Aripiprazole 10-30 (30) 3-5 75-94 4,9 87 99
Paliperidone 3-12 (15) 1,5 24,8 6,9 28 74
F (Bioavailability); BPP (Binding plasmatic proteins).















Renal excrection Hepatic metabolism
Approximately 60% of the dose
excreted unchanged in the urine
Minimal biotransformation







Figure 1: Metabolism and elimination of risperidone and paliperidone. Modified 
from Spina and Cavallaro [19].
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they usually undergo what is termed the first-pass effect, which causes 
their bioavailability to decline, but this varies widely depending on the 
antipsychotic (from 10% to 80%) [30]. 
One of the pharmacokinetic objectives of paliperidone ER is to 
achieve steady plasma levels with one daily dose. In other words, the 
aim is to have little fluctuation between peaks and troughs to minimize 
the occurrence of the adverse effects often linked to elevated levels of 
the primary active metabolite (Figure 2). Paliperidone in the form of 
ER tablets is pharmacokinetically linear within the recommended 3 to 
12 mg dose interval. The area under the curve is proportional to the 
administered dose and Tmax (time it takes to reach the highest plasma 
concentration of the drug) and falls within the 20 to 25-hour range for 
all once-daily doses [31]. 
In one study, healthy research volunteers (n=4) were administered 
one 6 mg dose of paliperidone ER. On average, their highest plasma 
concentration (Cmax) was 11.7 ng/mL, the time it took to reach that 
maximum concentration was 25.1 hours, and their ABC from 0 to 48 
hours was 302 ng·h/mL [31,32]. Repeatedly administering paliperidone 
ER produces stable, balanced concentrations on the fourth or fifth day, 
the (+) enantiomer’s ABC being 1.6 times greater than that of the (-) 
enantiomer [32]. Likewise, the index of fluctuation between maximum 
(peak) and minimum (trough) plasma concentrations after reaching 
equilibrium, is three times lower for paliperidone ER (38%) than for 
oral risperidone (125%). This finding, that paliperidone ER’s level in 
the plasma fluctuates less, provides differential data to support the 
argument that it is more tolerable. In fact, paliperidone’s gradual 
absorption means an initial dosage spike is not necessary in order to 
avoid orthostatic hypertension; in contrast, that is recommended in the 
case of risperidone [19]. 
Another interesting piece of data to take into account has to 
do with bioavailability. While paliperidone in solution (drug not 
commercialized) has almost total bioavailability, paliperidone ER’s 
bioavailability is around 28%. This difference is likely due to the 
fact that a considerable amount of osmotic paliperidone is released 
in the colon, where there is less absorption [19]. On that point, oral 
risperidone possesses an absolute bioavailability of 70%, which to our 
understanding could begin to explain the dose ratio (2:1) employed 
by some clinicians in patients who have been previously treated with 
risperidone and are being switched to paliperidone ER [23]. 
On the other hand, taking paliperidone ER with food that is high in 
fat and calories, compared to taking it while fasting, increases Cmax and 
ABC to 50-60%; Tmax and elimination half-life (T1/2) are hardly affected 
at all [33]. This seems to be due to ingestion slowing paliperidone ER’s 
movement in the upper part of the digestive tract, thereby increasing 
absorption. For that reason, patients should always take paliperidone 
tablets under the same conditions (with or without food) to avoid 
fluctuations in plasma levels of the drug. 
Metabolism
Metabolism of antipsychotic drugs in the liver is usually quite 
intense and complex, but in the case of risperidone, isoenzyme 
CYP2D6 is most critical [34,35], because it converts the drug through 
hydroxylation into its primary active metabolite, 9-OH-risperidone, or 
paliperidone [36,37]. 
In contrast to the case of risperidone and other antipsychotics, 
paliperidone’s metabolism in the liver is very limited; 60% of the 
molecule is eliminated, unaltered, in the urine (Figure 1). The rest is 
eliminated in the form of urinary metabolites through dealkylation 
(4.6%), hydroxylation (3.8%), dehydrogenation (2.7%), and break-
down of the benzisoxazole nucleus (4.1%), and a small amount in 
faeces. Even though in vitro studies have demonstrated that isoenzymes 
CYP2D6 and CYP3A4 can intervene in paliperidone metabolism, there 
are no in vivo data available to confirm whether or not said isoenzymes 
play a significant metabolic role. In a study of five healthy volunteers, 
after a single 1mg dose of immediate release paliperidone was taken 
orally, no metabolite was detected in the plasma [36,37]. 
Furthermore, in vitro studies of human, hepatic microsomes in 
subjects with genotypes UGT1A1 and UGT1A6 found that those 
enzymes do not influence paliperidone metabolism either [36,37]. 
Keep in mind that when other antipsychotic, substrates but 
not inhibitors of CYP450, are metabolized, their metabolism can be 
altered by inductors or inhibitors of isoenzymes, and pharmacokinetic 
interactions may occur. In the case of paliperidone, in vitro studies, 
conducted with human hepatic microsomes, confirmed the substance 
was neither a substrate nor a substantial metabolic inhibitor of 
medications metabolized by isoenzymes in cytochrome P450, like 
CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and 
CYP3A5 [36]. Therefore, that type of interaction is unlikely to occur. 
This salient pharmacokinetic feature can be applied clinically 
in that paliperidone may benefit patients with liver failure, not only 
because it minimizes liver damage, but also because drug accumulation 
in the plasma is not possible for such patients [27]. 
Another noteworthy piece of differential data between risperidone 
and paliperidone lies in the presence of genetic polymorphism in the 
various isoforms in cytochrome P-450. CYP2D6 is subject to so-called 
“genetic polymorphism” considering that between 5 and 10% of racially 
white individuals are slow metabolizers [38]. Risperidone is a substrate 
of that isoenzyme, so higher levels of it will remain in the blood plasma 
of poorer metabolizers longer, while it will be present in lower levels 
and for less time in fast metabolizers. 
Several clinical studies have shown that paliperidone is more 
stable in blood plasma than risperidone, due on the one hand to its 
special, extended absorption pharmaceutical mechanism, and on the 
other, to the fact that it is not affected by genetic changes in CYP450 
[39]. On a similar note, studies by Vermeier et al. [36] have elucidated 
that none of paliperidone’s metabolites surpass 5%, with practically 
no difference between fast and slow metabolizers. These data seem 































Figure 2: Pharmacokinetic profile of paliperidone ER and risperidone: mean 
plasma concentration vs. time. Modified from Pani et al. [28], and Kapur et al. 
[29]. 
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with agents metabolized by the aforementioned isoenzymes, then, is 
unlikely and not very applicable to clinical practice [40]. In addition, it 
seems unnecessary to make special instructions or recommendations 
for slow-metabolizing patients. 
It seems unlikely that drug inductors or inhibitors in these 
enzymatic systems will alter paliperidone’s pharmacokinetics [19]. 
In that vein, paroxetine’s (20 mg/day) influence has been examined; 
CYP2D6 was shown to strongly inhibit the release of paliperidone ER 
(3 mg) in a total sample of 60 healthy volunteers, with no clinically 
significant differences observed in ABC or Cmax between groups 
treated with paliperidone alone, or paliperidone and paroxetine [41]. 
By the same token, no serious adverse effects or important clinical 
changes occurred in either group in terms of laboratory results, vital 
signs, or ECG, so beginning or ending concomitant treatment with 
pharmaceuticals inhibiting CYP2D6 would not seem to require any 
dose adjustment in paliperidone ER [41]. 
In contrast, several studies have reported that fluoxetine [42,43] 
and paroxetine [44,45] can both bring about an increase in risperidone 
levels, to the extent that it would be clinically relevant. Also, risperidone 
has a weak ability to inhibit CYP2D6 and serum levels of clozapine 
increase about 74% following a 2 mg daily dose of risperidone [46]. 
Paliperidone’s lack of metabolic drug interactions was definitively 
established by Tomlinson’s [32] study, which included data collected 
from several clinical trials and a total sample of 616 schizophrenic 
patients being treated with paliperidone ER. The sample included 
slow metabolizers of CYP2D6. The study concluded there were no 
differences in the incidence of adverse effects between patients with the 
slow metabolizing phenotype and those with the normal phenotype. 
In light of these data, it could be concluded that one of paliperidone’s 
most important advantages over risperidone is its minimal hepatic 
biotransformation, which reduces the risk of clinically relevant 
drug interactions [27]. This is especially important considering that 
psychotic patients tend to present with comorbid pathologies requiring 
concomitant medications. It is therefore crucial that antipsychotics 
with little potential drug interaction be made available [47]. 
Distribution
A drug’s distribution through an organism’s different compartments 
depends on various factors, including the molecule’s size, its solubility 
in lipids/water, and the extent of its plasma protein binding. In that 
vein, paliperidone’s distribution is quick and extensive, as evidenced 
by its apparent Vd, which is on the order of 487 L. Similarly, it gets 
well-distributed throughout the CNS according to the findings of 
displacement studies of 11C-raclopride that utilized positron emission 
tomography (PET) in a sample of healthy volunteers [31]. However, 
different quantities of risperidone and paliperidone do really manage 
to reach the central nervous system. 
Plasma protein binding: Paliperidone, at therapeutic plasma 
concentrations between 50 and 250 ng/mL, binds primarily to α1-acid 
glycoproteins and albumin at a rate of 74% (82% for the (+) enantiomer 
and 65% for the (-) enantiomer), and this binding seems to be 
uninfluenced by gender, age, or renal functioning [19]. This binding is 
lower than that of risperidone, which binds to 90% of plasma proteins 
[48]. Paliperidone’s lower propensity to bind with plasma proteins even 
further reduces its possible interactions with other drugs. In fact, in 
vitro studies conducted with high concentrations of several substances 
that bind to plasma albumin (diazepam, warfarina, carbamazepina) 
only produced a slight increase in available paliperidone [31], 
leading us to believe that pharmacological interactions via protein 
displacement are unlikely with paliperidone, and certainly less likely 
than with risperidone. 
Since paliperidone can bind to α1-acid glycoprotein, a special 
precaution must be taken for patients suffering from moderate to severe 
liver failure who therefore synthesize fewer of such proteins, as with 
all drugs that bind to α1-acid glycoprotein and albumin. Nevertheless, 
Boom et al. [49] confirmed that the pharmacokinetic profile of non-
plasma protein-bound paliperidone was similar between patients with 
moderate liver failure and control subjects, so it is not necessary to 
adjust the dose in those patients. 
Structural differences influence paliperidone’s distribution in 
the brain: Placing a hydroxyl group in position 9 of the risperidone 
molecule, a seemingly small chemical change, creates structural 
differences between the two products that affect its passage through 
the BBB. Accordingly, the Brain/Blood ratio (logB/B) of paliperidone 
(logB/B= -0.67) is five times less than risperidone’s (LogB/B =-0.02) 
[50,51]. Paliperidone has less cerebral distribution for various reasons. 
First, there is a known, high correlation between a compound’s 
dynamic polar molecular surface area and its ability to permeate 
cellular membranes, particularly the blood-brain barrier (BBB), 
through passive diffusion. The presence of an OH group at position 
9 in paliperidone’s molecular structure lends it greater dynamic 
surface area (74.28 A2) than risperidone has (57.32 A2). This makes the 
correlation between cerebral and plasma drug concentrations higher 
for risperidone. While both drugs can enter the CNS through passive 
diffusion, because paliperidone’s dynamic polar surface area falls below 
the threshold of 120 A2 [52], it does so more slowly, or less so, than 
risperidone. 
Katritzky et al. [53] recently developed computerized models 
(CODESSA-PRO and ISIDA) to calculate blood/brain barrier 
coefficients (log BB), a measure of a drug’s penetration of the BBB, 
estimating values between -0.18 and -0.24 for risperidone and between 
-0.98 and -0.70 for 9-OH-risperidone, respectively. These data indicate 
that risperidone and paliperidone both cross the BBB, but risperidone 
does so to a greater extent. This pharmacokinetic data may explain 
some of the existing differences in the two drugs’ clinical profiles, and 
in the dosages of each substance recommended in clinical practice. 
P-glycoprotein and differential cerebral distribution of 
paliperidone vs. risperidone: P-glycoprotein, or Pgp (Permeability-
glycoprotein) is a protein in the glycated, phosphorylated plasma 
membrane, one of large dimensions (170 kDa) that is broadly 
distributed throughout the organism. It acts as a detoxifying and 
defense mechanism against what are referred to as anatomical 
“sanctuary sites” [54,55], eliminating or pumping toxic agents and 
xenobiotics, including drugs, from the inside of the cell by means of 
an ATP-dependent pump mechanism [56,57]. Pgp inhibition increases 
systemic exposure and tissue distribution of Pgp substrates, while its 
induction has the opposite effects [58-60]. 
According to studies conducted in vitro, among antipsychotics, 
risperidone and quetiapine are considered good substrates and 
therefore potential Pgp inhibitors. Both olanzapine and chlorpromazine 
are intermediate substrates, while clozapine and haloperidol are 
considered poor substrates [61]. 
Paliperidone (149.6 ± 29.7 mM) has much lower affinity than 
risperidone (26.3 ± 5.5 mM) for Pgp [62,63]. Zhu et al. [64] looked 
at cellular overexpression of Pgp (LLC-PK1/MDR1), finding that 
risperidone was between 3.8 and 2.2 times more inhibitory of Pgp than 
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paliperidone at the same concentration (Figure 3). Likewise, studies 
of knockout (KO) mice lacking Pgp reported a brain/blood ratio 14 
times higher in KO mice than control mice for risperidone, and 11 
times higher for 9-OH-risperidone; these differences were statistically 
significant [62]. In addition, they discovered significant differences 
between KO and control mice in brain/blood and brain/brain ratios for 
paliperidone [55-61]. Altogether, these data suggest that paliperidone, 
at least at therapeutic concentrations, cannot be considered a PgP 
inhibitor, differentiating it from risperidone [51-65]. Therefore, its 
presence in the CNS is limited by its expulsion through the PgP efflux 
pump. What is more, it seems unlikely that paliperidone interferes 
to a clinically relevant extent with the functioning of P-glycoprotein, 
whether encouraging its accumulation or that of other drugs at the 
cerebral level [66]. 
In light of the above, though no studies have been conducted in 
humans, mounting evidence collected in animals and through in 
vitro studies supports the notion that paliperidone has more difficulty 
penetrating the CNS than risperidone. This may explain risperidone’s 
higher potency and toxicity compared to paliperidone. Furthermore, 
higher plasma concentrations of paliperidone are needed to reach 
levels in the brain similar to those of risperidone [23]. 
Elimination
As discussed above, paliperidone may be considered to have a 
low index of hepatic extraction in that its plasma clearance (80 ml/
min) is somewhat lower than its hepatic plasma flow (700 ml/min). 
Paliperidone’s elimination half-life (T1/2) is 20-25 hours regardless 
of dose, how it is administered, and pharmaceutical formulation. 
Generally speaking, paliperidone is excreted mostly in the urine (80%) 
unaltered (60%), while a small amount is excreted as feces (11%). As 
for renal clearance, the clearance of unaltered paliperidone is 53 ml/
min; 50% of that is through glomerular filtration (CLGFR: 25.9 ml/min) 
and the other 50% through active mechanisms (CLACT: 27.2 ml/min) 
[19,31]. 
Tubular secretion through active transport seems to play a critical 
role in eliminating 9-OH-risperidone, probably via organic cation 
transport. Nevertheless, administering trimethoprim, a strong inhibitor 
of organic cation transport, does not significantly affect paliperidone 
ER’s pharmacokinetic parameters [67]. 
Bear in mind that paliperidone clearance is proportional to renal 
functioning, such that in patients with severe renal failure, it is 71% 
lower than in control subjects. Similarly, in patients with slight renal 
failure (renal clearance of creatinine between 50 and 80 ml/min), 
doses of paliperidone ER should not exceed 6 mg/day. In patients with 
moderate-severe renal failure (creatinine clearance between 10 and 50 
ml/min), the maximum dose falls to 3 mg/day [19,31]. 
Half life (T1/2): One of the main differences between risperidone 
and paliperidone ER lies in their respective half lives (T1/2): 2.8h and 
24.8 hours (Table 1). T1/2 provides clinically applicable information by 
indicating the time the drug needs to be eliminated after treatment is 
discontinued, the number of doses per day, and fluctuation in plasma 
levels over the course of the day. T1/2 addresses the possible link between 
the drug’s permanence in the organism and its beneficial or harmful 
effects. In addition, T1/2 is a useful tool to evaluate the time needed for 
the drug to reach a steady state, and a valuable measure of its longevity 
in the organism. After administering medication, an estimated five 
half lives are needed to eliminate 96% of it, and almost six half lives to 
eliminate 98% [23]. 
With this in mind, and given risperidone’s short half-life (2.8 
h), taking it twice a day would result in lower peaks, making it more 
tolerable than a once daily dose. Conversely, paliperidone ER’s long 
half-life (24.8 h) allows for one daily dose for lower peaks, fewer 
fluctuations, and improved tolerability [23]. 
Pharmacodynamic Differences: Paliperidone Er Vs. 
Risperidone
Differences between paliperidone and risperidone are not limited 
to pharmacokinetic aspects; certain pharmacodynamic distinctions 
may have a clinical impact. Below, we will discuss the differential 
properties of paliperidone and risperidone within the framework of 
the hypothesized mechanism for atypical antipsychotics’ activity, and 
sources of adverse effects tied to receptor profile. 
Differential profile of paliperidone vs. risperidone and 
dopamine D2 receptors
In 1976, Solomon H. Snyder reported that neuroleptics were 
dopamine D2 receptor antagonists and that their effects were 
proportional to clinical potency and to extrapyramidal and endocrine 
effects [68]. Later, through neuroimaging studies (PET, SPECT) in 
humans, an antipsychotic effect was linked to blocking more than 
65% of D2 receptors. It was also established that occupancy levels over 
72% of D2 receptors located in the tuberoinfundibular pathway were 
responsible for prolactin elevation. Meanwhile, occupancy of over 80% 
of striatal D2 receptors yielded adverse extrapyramidal effects [69]. 
Hence, we must maintain the therapeutic window between 65% and 
80% to yield therapeutic effects with no extrapyramidal side effects. 
Precisely paliperidone differs from risperidone, among other 
things, on its ability to block dopamine D2 receptors. Along those lines, 
several experimental studies have shown paliperidone to occupy fewer 
of said receptors. Receptor occupancy (affinity), determined by ED50 
values (effective dose to occupy 50% of receptors) (nM) of dopamine 
D2 receptors in “ex vivo” rat brains: 2.92 nM for risperidone and 
much higher, 8.68 nM, for paliperidone [70]. These data convey that 
paliperidone’s D2 receptor affinity is approximately 3 times lower than 
risperidone’s (Figure 4).
By the same token, receptor binding studies have determined the 
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Figure 3: Capacity of Pgp inhibition by paliperidone vs. risperidone. Modified 
from Zhu et al. [64]. 
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“post mortem,” confirming risperidone’s higher affinity (Kd = 3.77 nM) 
for these receptors than paliperidone’s (Kd = 2.8 nM) [72]. 
Furthermore, neuroimaging studies of schizophrenic patients 
reported that paliperidone ER’s occupancy of striatal and temporal 
lobe receptors had ED50 values of 2.38 and 2.84 mg/day, respectively 
[50]. Earlier studies of risperidone found a striatal ED50 value of 1.2 mg/
day [73] and a limbic lobe ED50 value of 1.46 mg/day [74]. These studies’ 
findings suggest a 1:2 ratio between risperidone and paliperidone ER 
doses would be apt. 
In this study, paliperidone ER at a dose of 6 to 9 mg/day yielded 
occupancy of 70 to 80% of striatal and temporal lobe dopamine D2 
receptors. Paliperidone ER’s estimated occupancy of D2 receptors at 
a dose of 6 mg/day was around 72%. This dose could be considered 
suitable, because it maintains D2 receptor occupancy levels above the 
threshold of effectiveness, yet below the threshold of extrapyramidal 
side effects [50]. By the same token, it is accepted that antipsychotic 
efficacy be linked to D2 receptor occupancy in the basal ganglion over 
65%, but when occupancy exceeds 80-85%, extrapyramidal side effects 
increase [29]. Given paliperidone ER’s lower occupancy of D2 receptors, 
and that its plasma levels fluctuate less [75], it should in theory have 
less extrapyramidal effects than risperidone [76]. 
In addition, quantitative autoradiographic studies show that ED50 
two hours after administering the antipsychotic is lower for risperidone 
than paliperidone in several areas of the brain: the nucleus accumbens 
(ED50: 0.75 vs. 2), olfactory tubercle (ED50: 0.96 vs. 4.1), striatum (ED50: 
1.2 vs. 3.7), and the pars compacta within the substancia nigra (ED50: 1 
vs. 3.3). These data hold that risperidone has a greater capacity for D2 
receptor occupancy than paliperidone, and therefore more intensely 
blocks said receptors. This is an important consideration; to yield an 
antipsychotic effect equivalent to that of risperidone, one would need a 
higher dose of paliperidone [71]. 
In effect, there seems to be a certain correlation between plasma 
levels of antipsychotics and the incidence of extrapyramidal symptoms. 
In the case of risperidone, the dosage threshold for parkisonism is 
around 6 mg/day [77], somewhat lower than that of paliperidone ER. 
However, dose is not the sole influence in the genesis of 
extrapyramidal side effects; fluctuations in antipsychotics’ plasma 
levels also seem to be of considerable import. For example, Yoshimura 
et al. [78] established in schizophrenic patients that a 4 mg/day dose 
of risperidone produced extrapyramidal side effects only in patients 
who exhibited plasmatic fluctuations of the antipsychotic and its 
metabolite. Nevertheless, with longer-lasting risperidone injections, 
fewer extrapyramidal side effects occurred. That may be due to the fact 
that the injectable drug’s Cmax (maximum concentration) in plasma was 
30% lower than in tablet form. The tablets are associated with fewer 
plasmatic fluctuations [79]. 
There are fewer fluctuations in plasma levels of paliperidone ER, 
which is considered one of the osmotic drug form’s best attributes. In 
a study conducted in a sample of 4 healthy volunteers administered 
a single, 6mg dose of paliperidone ER, average dopamine D2 receptor 
occupancy was 64% after 22 hours and 53% after 56 hours [80]. A 
different study by the same research group examined paliperidone 
ER’s striatal D2 receptor occupancy compared to an immediate release 
pharmaceutical form (drug not commercialized), reporting minimal 
fluctuation in D2 receptor occupancy (75-78%), 6 times lower than what 
was obtained with immediate release paliperidone (64-83%) [26,81]. 
This slight fluctuation in paliperidone ER at nigrostriatal D2 receptors 
translates to a favorable profile in terms of extrapyramidal side effects; 
this was confirmed in clinical trials of this antipsychotic [82]. 
According to an analysis of data collected from several clinical 
studies, rates of extrapyramidal effects associated with paliperidone ER 
doses of 3 and 6mg/day were similar to those observed with a placebo 
[83]. However, at higher doses (9 and12mg/day), extrapyramidal effects 
increased, surpassing what was observed in the placebo condition. 
These effects were categorized as slight or moderate and only two 
patients discontinued treatment because of said effects [84]. A year-
long study reported that no patients worsened due to extrapyramidal 
side effects, and a drop-out rate of less than 1% [85]. The incidence 
of extrapyramidal side effects in elderly individuals treated with 
paliperidone is generally low, with hypertonia, tremor, and akathisia 
occurring in only two of the study’s 76 patients (3%). In patients taking 
the placebo, akathisia was reported in one case. During the 6-month 
span, none of the elderly individuals treated with paliperidone ER 
discontinued treatment due to secondary, extrapyramidal issues [86]. 
On the other hand, risperidone and paliperidone are known to 
heighten prolactin secretion. Risperidone causes dose-dependent 
hyperprolactinemia [87,88], which some studies have shown [89-90], 
correlates directly with its metabolite, 9-OH-risperidone. In a 6-day 
study comparing the two substances, paliperidone ER at a dose of 12 
mg/day was found to produce an increase in serum concentrations of 
prolactin similar to what risperidone would produce at 4 mg/day [91]. 
Paliperidone ER, at 3 daily doses of 12mg/day, had an incidence of 
adverse effects related to prolactin elevation (1-2%) similar to what was 
observed in the placebo condition, but that rate went up (4%) when the 
dose of paliperidone ER rose to 15 mg/day [85]. Keep in mind that the 
dopamine receptors that control prolactinemia are not protected by the 
BBB, so plasma levels of the antipsychotics are responsible for higher or 
lower prolactin release [92]. In that sense, we know paliperidone crosses 
the BBB less than risperidone, which could explain the risperidone 
metabolite’s involvement in prolactin release. 
Speed of dissociation from the dopamine D2 receptor for 
paliperidone vs. risperidone
Another way to explain how an antipsychotic could improve 
extrapyramidal tolerability is the speed with which it dissociates from 
the D2 receptors [93,94]. It is been demonstrated that some atypical 
agents have the ability to dissociate quickly from the receptor, while 
classical drugs do so more slowly. 
By way of example, note that the speed of dissociation 
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Figure 4: Receptor profile of risperidone vs. paliperidone (“in vitro” data) (nM 1/
Kd x 100). Modified from Schotte et al. [71].
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chlorpromazine, and raclopride (around thirty minutes). Some atypical 
antipsychotics exhibit an intermediate speed of dissociation from the 
D2 receptor, including olanzapine, asenapine, sertindole, ziprasidone, 
and risperidone. However, other atypical antipsychotics dissociate 
quickly, like clozapine, quetiapine, amisulpride, remoxipride, and 
paliperidone, in nearly 1 minute [76]. In terms of dissociation speed, 
paliperidone fits the latter profile (Figure 5). 
Kapur and Seeman [93,94] suggest that fast dissociation from 
dopamine D2 receptors, in addition to producing an antipsychotic 
effect as a dopamine antagonist, better accommodates physiological 
dopamine transmission, so fewer of the extrapyramidal effects 
associated with nigrostriatal modulation occur. Furthermore, by 
enhancing the functioning of endogenous dopamine binding, these 
antipsychotics bear cognitive and emotional benefits and improve 
negative symptoms displays data on dissociation from dopamine D2 
receptors for a series of antipsychotics studied in vitro. It is noteworthy 
that paliperidone’s dissociation time from human cloned D2 receptors 
is noticeably lower (1 minute) than risperidone’s (27 minutes) [76]. 
Clearly, the theory of fast dissociation from the receptor (fast-off) is 
not valid for every antipsychotic that behaves atypically, yet it does 
draw a distinction between the behavior of risperidone (slow-off) and 
its active metabolite, paliperidone (fast-off). 
Thus, a paradigm shift has occurred from considering 
extrapyramidal effects to be an outcome of the proportion of receptors 
blocked (usually over 80%), to an outcome of the antipsychotic’s speed 
of dissociation from the receptor, such that more adverse effects occur 
the longer the antipsychotic takes to leave a given D2 receptor [95]. This 
hypothesis would explain paliperidone’s low risk of extrapyramidal 
effects considering, its fast dissociation. 
On the other hand, the incidence of extrapyramidal effects reported 
in risperidone use, especially at high doses, may be due to its high 
capacity for D2 blockade, coupled with slow dissociation speed. Ergo, 
its atypicality can be explained by other mechanisms. First of all, its 
higher capacity for 5-HT2A blockade speaks to the drug’s atypicality. 
Yet it is also crucial to consider that risperidone is converted into its 
active metabolite, 9-OH-risperidone, which quickly dissociates from 
dopamine D2 receptors, so the higher the rate of conversion into its 
metabolite, the fewer extrapyramidal effects it will have. 
Serotonin 5-HT2A receptor occupancy>D2 as hypothesis for 
atypicality
Presently, the most plausible hypothesis for the “atypicality” of 
antipsychotics posits “dopamine-serotonin antagonism” and was 
conceived of by Janssen et al. [96] and popularized by Meltzer et al. 
[97]. According to this theory, greater ability to block 5-HT2A than D2 
receptors (5-HT2A>D2) confers atypicality to an antipsychotic. Along 
those lines, 5-HT2A antagonism can increase dopaminergic transmission 
in the nigrostriatal pathway, reducing the risk of extrapyramidal 
effects. Furthermore, this relationship of 5HT2A>D2 blockade in the 
prefrontal cortex would improve negative, cognitive symptoms of 
schizophrenia by increasing dopamine and acetylcholine release [98]. 
However, 5-HT2A blockade does not affect the mesolimbic pathway, so 
it would not increase dopamine release in that area, leaving the atypical 
agent’s antipsychotic properties unhindered [99]. Most antipsychotics’ 
atypicality, asenapine, clozapine, iloperidone, olanzapine, paliperidone, 
quetiapine, risperidone, sertindole, ziprasidone, and zotepine, for 
example, could be explained by this hypothesis since they all blockade 
5-HT2A and D2 receptors such that5-HT2A>D2 [100,101]. 
In that vein, the hypothesis above does not contradict that of 
Kapur and Seeman [93,94] about speed of dissociation from D2 
receptors; rather, they complement one another. Increased dopamine 
release, a secondary effect of 5-HT2A, facilitates antipsychotics’ speed of 
dissociation from its receptors [16]. 
Notwithstanding that contribution, this hypothesis is not without 
limitations. For example, the atypical antipsychotic amisulpride has 
low affinity for 5-HT2A receptors. Aripiprazole has greater D2 affinity 
than 5-HT2A affinity despite being an atypical antipsychotic. Also, two 
classical antipsychotics, chlorpromazine and loxapine, have greater 
affinity for 5-HT2A than D2, yet they do not meet the atypical profile. 
Additionally, risperidone and olanzapine, which exhibit 5-HT2A>D2 
receptor occupancy, can cause extrapyramidal effects at high doses 
despite very elevated 5-HT2A occupancy. Therefore, higher 5-HT2A>D2 
affinity may promote dopamine release in the striatum and prefrontal 
cortex, but it does not protect against extrapyramidal symptoms if D2 
receptor occupancy passes a certain threshold [101,102]. Therefore, 
these receptors’ participation in atypical antipsychotic activity seems 
to be more a result of dominance in dopamine D2 blockade than of 
isolated 5-HT2A antagonist ability. Moreover, higher doses of atypical 
agents could make that dominance disappear [95]. Despite these 
limitations, the hypothesis that best captures atypicality is the one that 
postulates greater 5-HT2A blockade than D2 blockade [95,103]. 
With the above in mind, utilizing neuroimaging techniques in 
schizophrenic patients being treated long-term with antipsychotics, 
it has been observed that risperidone’s occupancy is approximately 
80% for dopamine D2 receptors in the striate nucleus, and between 86 
and 93% for serotonin 5-HT2A receptors in the cerebral cortex. Other 
authors reported similar data about clozapine, olanzapine, quetiapine, 
and ziprasidone [104-108]. In contrast, administering classical 
neuroleptics blocks between 70 and 90% of striatal D2 receptors and 
does not significantly occupy serotonin 5-HT2A receptors [100,109]. 
Paliperidone’s binding to 5-HT2A receptors is 0.25 nM, compared 
to risperidone’s 0.16 nM [76]. Data collected in rats by Schotte et 
al. [70] are on the order of 0.15 nM for risperidone and 0.82 nM for 
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Figure 5: Time of antipsychotic drug dissociation from the D2 receptor (50%). 
Modified from Seeman [76].
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is lower than risperidone’s. However, paliperidone’s ability to block 
5-HT2A receptors is almost 20 times higher than its blockade of D2 
receptors, fitting the hypothesis that antipsychotics’ atypicality lies in 
their serotonin vs. dopamine antagonism. 
The fact that paliperidone ER exhibits receptor occupancy such 
that 5-HT2A>D2 with little plasma fluctuation, the ability to gradually 
occupy D2 receptors, and quick dissociation from said receptors, are 
all grounds to consider it an atypical antipsychotic with a lower risk of 
extrapyramidal side effects than risperidone has [76,110]. 
Occupancy of other receptors by paliperidone and risperidone
In general, antipsychotics are not very selective from the 
perspective of receptors, so their activity at non-target receptors ought 
to be considered, since that can alter overall neural performance and is 
responsible for certain therapeutic peculiarities and above all, adverse 
effects. Many of these agents simultaneously interact with different 
types of receptors (dopaminergic, serotonergic, histaminergic, 
α-adrenergic, muscarinic), which has an impact on the overall response 
of neurons and functional systems involved in their effectiveness and 
tolerability [111]. Though not all functions of each receptor are exactly 
known, understanding each antipsychotic’s receptor profile, heeding 
its efficacy and any secondary effects is useful in guiding patients 
toward choosing an appropriate medical regimen [112]. 
5-HT2C receptor blockade seems to be closely linked to 
antipsychotic-induced weight gain, but it is not solely responsible for 
weight gain [113,114]. Neither risperidone nor paliperidone is believed 
to show significant affinity for said receptor. 
Some antipsychotics can boost appetite and weight by jointly 
blocking receptors 5-HT2C and H1 [115]. H1 and 5-HT2C-antagonist 
antipsychotics include clozapine, olanzapine, and quetiapine, and 
correlate with weight increase in patients. 
Despite the fact that risperidone has lower H1 receptor affinity, 
weight gain is also associated with the atypical agent, especially in 
children and adolescents [116]. Paliperidone has less affinity for 
receptors 5-HT2C and H1 than risperidone, so weight gain should be 
more moderate. An analysis of the data collected in three controlled 
studies elucidated that paliperidone ER was no different from the 
placebo after 6 weeks of treatment, in terms of weight, lipid parameters, 
or blood sugar [117]. Nevertheless, an additional increase of 1.2 
kilograms was observed in patients who continued treatment with 
paliperidone ER in three randomized studies conducted over the 
course of 52 weeks [118]. 
Certain antipsychotics’ ability to block adrenergic α1 receptors seems 
to explain their potential to bring about cardiovascular or orthostatic 
effects, erectile dysfunction (impotence), akinesia, and sedation. 
Risperidone is one such drug (Kd=2.7 ± 0.3 nM). Paliperidone’s affinity 
for these receptors is almost 4 times lower than risperidone’s. However, 
there are data that point to possible orthostasis, but that risk is lower 
than in the case of risperidone [118]. 
Likewise, certain atypical antipsychotics can also block α2-
adrenergic receptors. Risperidone is among the drugs most capable 
of blocking these receptors (Kd=8 ± 1 nM). α2-adrenergic receptors in 
the prefrontal cortex promotes dopamine release and can contribute to 
the cognitive improvement that antipsychotics bring about [95,100]. 
Paliperidone has less affinity for said adrenergic receptors (Kd=80 ± 10 
nM) than risperidone [72]. 
Paliperidone has a low affinity for muscarinic receptors, producing 
scarcely any central or peripheral anticholinergic effects [119]. What is 
more, said lack of anticholinergic effects may be beneficial in terms of 
certain psychotic symptoms, like visual hallucinations, disorientation, 
and agitation, and in the cognitive sphere (learning and memory), but 
these hypotheses must be compared through apt, specific clinical trials 
[27]. Paliperidone has low β-adrenergic receptor affinity [72]. 
The differential electrophysiological profile of paliperidone 
vs. risperidone
A neuron’s electrophysiological behavior is a manifestation of 
pharmacological activity at its different receptors. Along those lines, 
risperidone is known, independently of dose, to inhibit neuronal 
release of serotonin, while paliperidone is unable to modulate that 
release. Recovery of serotonin release inhibited by risperidone can be 
achieved by jointly administering a 5-HT1A (WAY 100635) receptor 
blockade and a norepinephrine reuptake inhibitor (desipramine). 
Hence, we can conclude that risperidone inhibits the release of 5-HT 
neurons by activating autoreceptors 5-HT1A and blocking α1 receptors, 
leading us to believe paliperidone is less active at these two receptors 
than risperidone [110]. 
Although paliperidone does not alter norepinephrine release per 
se, it can revert escitalopram-induced suppression of norepinephrine 
release without changing the SSRI’s role in serotonin release. This can 
be a useful adjuvant treatment in refractory depression. Similarly, 
paliperidone can be considered different from other atypical 
antipsychotics. It does not inhibit neuronal release of serotonin like 
olanzapine and clozapine by inhibiting α1 receptors, and unlike 
ziprasidone and aripiprazole, it is not a 5-HT1A receptor agonist 
[110]. The differences between paliperidone and risperidone, as far as 
norepinephrine release in vivo, may be due to its low capacity to bind 
at 5-HT2A and α1-receptors, observed in vitro [71]. 
Differential profile of paliperidone: neurotoxicity and 
neuroprotection
Recent studies’ findings suggest that some atypical antipsychotics 
may have a neuroprotective impact that could be involved in cognitive 
improvement, or at least preventing the progression of an illness and 
its associated impairment, though these effects have not been reported 
consistently [120]. On another note, antipsychotics’ neurotoxic effects 
have been linked to secondary effects, particularly extrapyramidal side 
effects and tardive dyskinesia. It is been demonstrated in vitro that 
classical antipsychotics, including haloperidol, reduce neuronal cells’ 
viability [121], causing apoptosis, necrosis, and increasing oxidative 
stress [122,123]. Furthermore, in vitro studies have shown that while 
haloperidol is apparently neurotoxic, some atypical antipsychotics 
have shown antiapoptotic properties [124]. 
On another note, it has been shown that haloperidol, through 
intracellular accumulation of peroxides followed by depletion of 
intracellular glutathione, can cause oxidative stress in hippocampal cells 
[125]. Classical antipsychotics, clozapine, quetiapine, and risperidone 
can protect PC12 cells by regulating the expression of copper/zinc-
dependent superoxide dismutases (SOD1) [126]. 
In an ex vivo study, paliperidone induced expression of proteins in 
the prefrontal cortex similar to that of lithium and valproic acid. These 
changes could affect oxidative phosphorylation, electron transport, 
metabolism of carbohydrates, and postsynaptic signal transduction. 
According to these results, like lithium and valproic acid, paliperidone 
is involved in neuronal signaling pathways, energetic metabolism, 
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and synaptic plasticity, so it is postulated to have a mood stabilizing 
mechanism like that of lithium and valproic acid [127]. 
Haloperidol and the atypical antipsychotic clozapine have been 
reported to have toxic effects in both neuroblastoma cell lines (SH-
SY5Y) and monocytes (U937). Both cell lines are considered to be 
involved in the pathogenesis of schizophrenia. In this model, low 
concentrations of risperidone (1.6–12.5 μg/mL) increase cell survival, 
while paliperidone significantly improves survival of SH-SY5Y cells 
and U-937 cells at a concentration of 1.6 μg/mL [128]. 
A study of SH-SY5Y cells was conducted, applying various 
aggressive substances (MPP+, Aβ25-35 and hydrogen peroxide) during 
treatment with antipsychotics: haloperidol, olanzapine, risperidone, 
and paliperidone. After 24 hours of treatment, paliperidone had the 
lowest basal toxicity over other antipsychotics. Furthermore, the group 
treated with paliperidone showed significantly higher cell survival than 
the cultures treated with other antipsychotics. At low concentrations 
(10 and 50 μM), paliperidone showed itself to be effective against Aβ25-
35 and MPP+. In addition, paliperidone was the only antipsychotic that 
could protect SH-SY5Y cells against hydrogen peroxide. 
It (100 μM) completely diminished cell death caused by 
the aggressive substances mentioned above, regardless of their 
concentration. Compared to other antipsychotics, paliperidone proved 
better able to control oxidative stress by generating glutathione, 
decreasing HNE (4-hydroxy-2-nonenal), and producing carbonyl. 
Olanzapine, on the other hand, under similar conditions, increased 
HNE and carbonyl production, which might explain its cytotoxicity 
[33]. 
A recent study conducted on cultures of human neuroblastoma 
cells compared the effects of haloperidol, risperidone, and paliperidone 
(10, 50, 100 μM), both alone and accompanied by dopamine, on the 
cells’ viability and caspasa-3 activity. Haloperidol, both alone and 
accompanied by dopamine, significantly decreased cellular viability 
while increasing caspase-3 activity and cell death. In contrast, neither 
risperidone nor paliperidone had an impact on cellular viability or 
cell death. Both atypical antipsychotics’ caspase-3 activity declined, 
especially paliperidone’s. In cells treated with dopamine as well as 
an antipsychotic, only paliperidone (10 μM) brought about slight 
improvement in cellular viability. While haloperidol sparked a 
dopamine-induced increase in caspase-3 activity, risperidone and 
paliperidone showed less of such an effect. These results reveal that 
haloperidol causes apoptosis, while risperidone and paliperidone can 
protect against apoptosis. Along those lines, paliperidone consistently 
showed itself to be strongest neuroprotector of the group [124]. 
These data together suggest that paliperidone, from the point of 
view of neurotoxicology and neuroprotection, behaves differently from 
classical and other atypical antipsychotic drugs, also setting itself apart 
from risperidone. 
Conclusions
Paliperidone, as active metabolite of risperidone, is quantitatively 
different from risperidone from the perspective of pharmacodynamics 
as well as pharmacokinetics. 
Experimental and clinical studies indicated that paliperidone ER 
differs from other classical and atypical antipsychotics, even from 
risperidone. Paliperidone ER’s theoretical advantages in terms of 
efficacy and tolerability, compared to risperidone and possibly other 
second-generation antipsychotics, are linked to its formulation, 
pharmacokinetics, and to a lesser extent, its pharmacodynamic profile. 
Paliperidone ER’s osmotic formulation (OROS technology) 
provides constant release of the primary agent for 24 hours and reduces 
fluctuations in plasma levels of the drug. This formulation allows for a 
single daily dose to be taken, which is easier to accomplish and does 
not require initial dose titration. On the other hand, paliperidone’s 
gradual, continuous release facilitates stable occupancy of D2 receptors, 
which can provide constant therapeutic effectiveness with fewer peaks 
and troughs, as well as a lower incidence of side effects. Paliperidone 
is hardly metabolized by CYP450 isoenzymes, which entails a lower 
probability of hepatic overload and, above all, drug interactions for 
patients with polypharmacy. 
Furthermore, paliperidone ER more quickly dissociates from 
dopamine D2 receptors than risperidone, which may indicate a 
lower incidence of extrapyramidal side effects. Paliperidone binds at 
α-adrenergic receptors less than risperidone, though that does not rule 
out risk of orthostatic hypertension. Also, it binds less at H1 receptors 
than risperidone and does not block 5-HT2C receptors, so its propensity 
for weight increase is considered intermediate within its atypical class. 
Paliperidone seems to be the metabolite responsible for risperidone-
induced prolactin secretion, probably because it crosses the BBB to 
a lesser extent, and receptors on the tuberoinfundibular pathway are 
unprotected. Last, paliperidone ER can prolong the QTc interval, so it 
must be used with caution in patients who are predisposed to cardiac 
irregularity. 
Finally, paliperidone’s possible neuroprotective role could 
differentiate its pharmacodynamic profile from that of other 
antipsychotics, including risperidone.
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